IRIX

+ Watchlist + Portfolio

IRIDEX Corp.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.63
52-Week Range: $0.61 – $1.65
Market Cap: $11.30M
P/E (TTM): —
EPS (TTM): -0.20
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: 0.94
Return on Equity: -73.15%
Return on Assets: -5.90%
Gross Margin: 35.92%
Operating Margin: -8.19%
Profit Margin: -6.88%
Current Ratio: 1.82
Debt/Equity: 1.10
Total Debt: $4.01M
Free Cash Flow: $1.64M
Revenue Growth: -7.40%
Earnings Growth: —
Enterprise Value: $16.63M

IRIX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$56.97M	$51.87M	$48.67M	$52.67M
Cost of Revenue	$31.60M	$30.06M	$29.17M	$33.45M
Gross Profit	$25.37M	$21.81M	$19.50M	$19.23M
Research & Development	$7.17M	$6.83M	$5.45M	$3.67M
Selling, General & Admin	$25.73M	$24.98M	$22.36M	$18.13M
Operating Expenses	$32.91M	$31.81M	$27.80M	$21.80M
Operating Income	-$7.54M	-$10.01M	-$8.30M	-$2.57M
EBITDA	-$6.16M	-$7.97M	-$6.88M	-$1.02M
Pretax Income	-$7.48M	-$9.48M	-$8.84M	-$4.38M
Income Tax	$65.00K	$90.00K	$68.00K	$57.00K
Net Income	-$7.55M	-$9.57M	-$8.91M	-$4.44M
Diluted EPS	-0.47	-0.59	-0.54	-0.26
Diluted Shares	15.94M	16.13M	16.44M	16.93M

IRIX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$13.92M	$7.03M	$2.39M	$6.03M
Receivables	$9.77M	$9.65M	$8.39M	$9.54M
Inventory	$10.61M	$9.91M	$10.82M	$7.88M
Current Assets	$35.77M	$27.45M	$23.56M	$25.25M
Total Assets	$42.29M	$34.44M	$29.14M	$29.15M
Current Liabilities	$12.45M	$12.97M	$16.56M	$13.21M
Long-Term Debt	—	—	$1.00M	$3.73M
Total Debt	$1.77M	$2.75M	$4.64M	$4.53M
Total Liabilities	$25.06M	$24.91M	$27.04M	$24.23M
Retained Earnings	-$69.72M	-$79.04M	-$88.01M	-$92.45M
Shareholders' Equity	$17.23M	$9.52M	$2.10M	$4.92M
Working Capital	$23.31M	$14.48M	$7.00M	$12.04M
Net Debt	—	—	$351.00K	—

IRIX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$9.52M	-$6.75M	-$7.29M	-$2.12M
Capital Expenditure	-$286.00K	-$109.00K	-$13.00K	-$143.00K
Free Cash Flow	-$9.80M	-$6.85M	-$7.30M	-$2.26M
Depreciation & Amortisation	$1.38M	$2.03M	$1.42M	$1.55M
Stock-Based Compensation	$1.62M	$1.65M	$1.24M	$775.00K
Investing Cash Flow	-$286.00K	-$109.00K	-$13.00K	-$143.00K
Financing Cash Flow	-$73.00K	-$5.00K	$2.60M	$5.96M
Net Change in Cash	-$9.88M	-$6.86M	-$4.69M	$3.71M

IRIX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$11.90M	$13.57M	$12.48M	$14.72M	$11.80M	$12.57M
Cost of Revenue	$6.84M	$8.89M	$8.47M	$9.25M	$7.06M	$8.27M
Gross Profit	$5.05M	$4.68M	$4.01M	$5.48M	$4.74M	$4.30M
Research & Development	$876.00K	$871.00K	$972.00K	$949.00K	$905.00K	$936.00K
Selling, General & Admin	$4.38M	$4.75M	$4.45M	$4.54M	$4.16M	$4.39M
Operating Expenses	$5.26M	$5.62M	$5.42M	$5.49M	$5.07M	$5.33M
Operating Income	-$205.00K	-$940.00K	-$1.41M	-$15.00K	-$324.00K	-$1.03M
EBITDA	$176.00K	-$562.00K	-$1.04M	$407.00K	$48.00K	-$667.00K
Pretax Income	-$1.67M	-$973.00K	-$1.57M	-$164.00K	-$466.00K	-$1.20M
Income Tax	$12.00K	$21.00K	$4.00K	$20.00K	$58.00K	$70.00K
Net Income	-$1.69M	-$994.00K	-$1.57M	-$184.00K	-$524.00K	-$1.27M
Diluted EPS	-0.10	-0.06	-0.09	-0.01	-0.03	-0.07
Diluted Shares	16.73M	16.79M	17.01M	17.19M	17.31M	17.42M

IRIX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$7.24M	$6.78M	$5.57M	$6.03M	$4.59M	$4.68M
Receivables	$9.39M	$10.03M	$9.53M	$9.54M	$8.42M	$7.09M
Inventory	$10.14M	$8.44M	$7.30M	$7.88M	$9.32M	$9.75M
Current Assets	$29.13M	$26.87M	$24.07M	$25.25M	$24.58M	$23.96M
Total Assets	$34.24M	$31.59M	$28.35M	$29.15M	$28.27M	$27.26M
Current Liabilities	$14.95M	$13.71M	$12.39M	$13.21M	$12.83M	$13.17M
Long-Term Debt	$3.64M	$3.67M	$3.71M	$3.73M	$3.77M	$3.79M
Total Debt	$5.30M	$5.07M	$4.79M	$4.53M	$4.28M	$4.01M
Total Liabilities	$33.38M	$25.53M	$23.67M	$24.23M	$23.54M	$23.62M
Retained Earnings	-$89.69M	-$90.69M	-$92.26M	-$92.45M	-$92.97M	-$94.24M
Shareholders' Equity	$852.00K	$6.06M	$4.68M	$4.92M	$4.73M	$3.64M
Working Capital	$14.18M	$13.16M	$11.67M	$12.04M	$11.76M	$10.79M

IRIX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.15M	-$397.00K	-$1.16M	$589.00K	-$1.33M	$174.00K
Capital Expenditure	-$11.00K	-$13.00K	-$13.00K	-$106.00K	-$101.00K	-$50.00K
Free Cash Flow	-$1.16M	-$410.00K	-$1.17M	$483.00K	-$1.44M	$124.00K
Depreciation & Amortisation	$381.00K	$378.00K	$366.00K	$422.00K	$372.00K	$362.00K
Stock-Based Compensation	$213.00K	$257.00K	$92.00K	$213.00K	$211.00K	$212.00K
Investing Cash Flow	-$11.00K	-$13.00K	-$13.00K	-$106.00K	-$101.00K	-$50.00K
Financing Cash Flow	$6.04M	-$14.00K	-$34.00K	-$27.00K	-$1.00K	-$38.00K
Net Change in Cash	$4.88M	-$424.00K	-$1.21M	$456.00K	-$1.44M	$86.00K

Market Snapshot

About

IRIDEX Corporation is a medical technology company that designs, develops, and manufactures ophthalmology laser systems and delivery devices. The company's products are used to treat a range of eye diseases including diabetic retinopathy, glaucoma, and retinal tears. IRIDEX's portfolio includes semiconductor-based laser consoles, delivery devices, and consumables used by ophthalmologists in clinical and surgical settings. The company focuses on developing innovative laser-based treatments that provide effective, minimally invasive therapeutic options for retinal and glaucoma patients worldwide.